L'intérêt à découvert pour Binah Capital Group donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Binah Capital Group. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Binah Capital Group (NASDAQ:BCG) Stock, Rapport sur les intérêts à découvert

Binah Capital Group

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

Binah Capital Group Inc

BCGF Acquisition Corp

Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) with a Buy and lowers the price target from $23 to $15.

News

Price Target

Analyst Ratings

CMPS

Canaccord Genuity Maintains Buy on Compass Pathways, Lowers Price Target to $15

Craig-Hallum analyst Anthony Stoss maintains Airgain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRG#NASDAQ">AIRG</a>) with a Buy and lowers the price target from $12 to $9.

AIRG

Craig-Hallum Maintains Buy on Airgain, Lowers Price Target to $9

No-fault laws are one of the contributing factors to why car insurance premiums climb higher in some states. Twelve states hold these rules and demand that your insurance covers your injuries after a crash despite who caused it.
What are no-fault laws? In a typical setup, the at-fault driver's insurance picks up the tab for your damages, but in no-fault states your own policy steps in to handle your injuries, regardless of blame. This hinges on Personal Injury Protection—PIP for short—a required coverage in these states. PIP takes care of costs tied to the accident including medical bills and lost wages. States like Florida, Michigan, and New York follow this system though each have their own set of rules regarding PIP and subsequent lawsuits.
Here's a twist: no-fault states often block lawsuits for pain and suffering unless injuries hit a serious mark—like severe harm or death. The goal? Fewer court battles and, ideally, lower premiums. But does this actually work out the way it is supposed to?
Supporters say no-fault laws smooth out the claims process because your insurer pays your PIP claim directly. This supposedly cuts delays and legal tangles. Fewer lawsuits over pain and suffering could trim administrative costs for insurance companies and if those savings stack up, they might show up as lower premiums, especially where lawsuit limits hold firm.
But there's a flip side. PIP coverage often costs more than optional medical payments in fault-based states. With its wide reach—covering medical expenses, lost income, and beyond—insurers face bigger payouts. Michigan once had unlimited medical benefits under PIP, sending premiums through the roof. Recent changes let drivers pick lower limits.
Fraud adds another layer to the insurance mess. In Florida and New York, staged crashes and padded claims have jacked up PIP expenses and insurers hit with these losses hike premiums to balance the books. Additionally every injured driver in a no-fault state files a claim with their own company, boosting claim numbers compared to fault-based systems. In at fault states, the number of claims files is half as it is usually only the at fault person filing.
As we&#8217;ve mentioned, insurance premiums depend heavily on where you live. High PIP limits, like Michigan's old standard, tend to mean pricier rates. Strict lawsuit caps can often hold costs down. Fraud also continues to be a huge issue and states that are able tackle fraud effectively can keep steady premiums.
Take Florida for example. Despite aims to curb litigation, fraud and lawsuits have pushed premiums far above the national average. Michigan's recent PIP adjustments hint that scaling back coverage can lighten the load. Other factors—accident frequency, medical costs, and city density—muddy the picture further.
If you live in a no-fault state it might be a good idea to check your PIP minimums to weigh if the extra coverage makes sense. Know your state's lawsuit threshold—it sets the bar for chasing damages beyond PIP. Adding uninsured or underinsured motorist coverage can shield you from drivers with skimpy policies, though PIP steps in either way.
Solid liability coverage matters in fault based states. If you cause a wreck, you'll cover the other side's damages. Optional medical payments coverage can act like PIP, but it often caps out lower.
In conclusion, are no-fault laws a true contributor to inflating premiums? It's a mixed bag. They can streamline claims and trim lawsuits and possibly cut costs. Mandatory PIP and fraud risks can nudge rates up. The real impact depends on your state's rules and broader trends. Understand your local setup and pick a policy that fits—your budget will feel the difference.

Legal

Exclusives

Personal Finance

Insurance

General

Do No-Fault Laws Drive Up Your Car Insurance Premiums?

Canaccord Genuity analyst George Gianarikas maintains Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) with a Buy and lowers the price target from $36 to $27.

AMRC

Canaccord Genuity Maintains Buy on Ameresco, Lowers Price Target to $27

Craig-Hallum analyst George Sutton maintains Globalstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NASDAQ">GSAT</a>) with a Buy and lowers the price target from $75 to $45.

GSAT

Craig-Hallum Maintains Buy on Globalstar, Lowers Price Target to $45

Nayax Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>), a global commerce enablement and payments platform, has acquired UPPay, a digital payment and telemetry provider for automated <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44040125/nayax-announces-the-acquisition-of-uppay" rel="noreferrer noopener">self-service coffee machines in Brazil.</a>
The purchase price, equating to an enterprise value of R$32.75 million (~$5.3 million), will be paid with cash on hand and includes the earnout amount of up to&nbsp;~$0.47 million.
Nayax entered the Brazilian market in 2024 when it acquired VMtecnologia, a technology provider for the automated self-service industry in Brazil. With the acquisition of UPPay, Nayax and VMtecnologia will serve more than 25,000 new unattended points of sale in Brazil.
UPPay will integrate operationally with VMtecnologia, consolidating both companies&#8217; sales, distributional, and technical expertise.
This strategic acquisition strengthens Nayax&#8217;s foothold in the Brazilian market and broadens its reach across Latin America, offering merchants a comprehensive suite of affordable payment solutions.
&#8220;UPPay&#8217;s sophisticated yet affordable platform complements our vision of empowering retailers of all sizes with real-time operational insights, streamlined payments, and seamless customer experiences,&#8221; stated Yair Nechmad, CEO and Chairman of Nayax.
As of September 30, 2024, the company had&nbsp;$89 million&nbsp;in cash and cash <a target="_blank" href="https://www.benzinga.com//node/41897468" rel="noreferrer noopener">equivalents and short-term deposits.&nbsp;</a>
Nayax&nbsp;will release its&nbsp;fourth quarter&nbsp;and 2024&nbsp;earnings on March 4, 2025.
Price Action: NYAX shares traded lower by 1.12% at $37.24 at last check Friday.
Photo via Shutterstock.

Equities

NYAX

Nayax Expands In Brazil With UPPay Acquisition, Taps Into New Payment Points

WIIM

NTLA

Intellia Therapeutics shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and cut its price target from $45 to $13. Additionally, Chardan Capital lowered its price target from $91 to $68.

Canaccord Genuity analyst Austin Moeller maintains Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Buy and raises the price target from $13 to $13.5.

ACHR

Canaccord Genuity Maintains Buy on Archer Aviation, Raises Price Target to $13.5

MTUS

Metallus shares are trading lower after the company reported a year-over-year decrease in Q4 adjusted EPS results and worse-than-expected revenue.

On Friday, ANI Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) reported fourth-quarter adjusted EPS of $1.63, up from $1 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.44</a>.
The company reported sales of $190.57 million, up 44.8% year over year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44038542/ani-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2024-financial-results-and-raises-" rel="noreferrer noopener">consensus of $175.37 million</a>.
On an organic basis, excluding the acquisition of Alimera, total net revenues grew 23.8% year-over-year.
Net revenues for rare diseases, which include Cortrophin Gel, Iluvien, and Yutiq, increased by 108.5% to $87.0 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296581/ani-pharmaceuticals-shifts-focus-from-generics-to-high-margin-brand-assets-analyst-" rel="noreferrer noopener">ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential</a>
Cortrophin Gel net revenues increased 42.3% to $59.4 million, driven by increased volume.
Iluvien and Yutiq generated net revenues of $27.6 million in the first full quarter <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39460281/generics-player-ani-pharmaceuticals-strengthens-rare-disease-segment-with-380m-alimera-sciences-d" rel="noreferrer noopener">following the acquisition of Alimera</a>.
Net revenues for Brands increased 58.9% to $19.8 million, driven by increased demand.
Net revenues for Generic pharmaceutical products increased 9.4% to $78.6 million, driven by increased volumes in the base business and the contribution from new product launches.
The company launched five new products during the quarter and 17 for the full year. ANI&#8217;s strong R&amp;D and commercial productivity continued into the first quarter of 2025 with the launch of Prucalopride Tablets with 180 days of exclusivity.
The company says momentum has continued in the first quarter of 2025, with the number of new cases initiated reaching a new high in February.
Brands&#8217; revenues increased 58.9% to $19.8 million, driven by increased demand for certain products, which has occurred periodically over the past two years.
While this additional demand has persisted into the first quarter of 2025, the company anticipates a normalized performance thereafter for the purpose of full-year 2025 guidance.
Guidance: ANI Pharmaceuticals expects 2025 revenues of $756 million—$776 million, versus prior guidance of $739 million—$759 million and a consensus of $724.71 million.
The company expects adjusted EBITDA of $190 million-$200 million compared to prior guidance of $182 million-$192 million.
&#8220;With our business off to a strong start in 2025, particularly Cortrophin Gel, Generics, and Brands, we are raising our 2025 guidance for total net revenues and adjusted non-GAAP EBITDA,&#8221; said Nikhil Lalwani, President and CEO.
ANI Pharmaceuticals expects 2025 adjusted EPS of $6.12-$6.49 versus a consensus of $5.56.
Price Action: ANIP stock is up 10.41% at $60.26 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/44043253/mplx-seals-715-million-deal-for-full-control-of-bangl-pipeline-details" target="_blank" rel="noreferrer noopener">MPLX Seals $715 Million Deal For Full Control Of BANGL Pipeline: Details</a></li>
</ul>
Image via Shutterstock

Earnings

Guidance

Health Care

Movers

Trading Ideas

ANIP

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast

Citizens Capital Markets analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) with a Market Outperform and lowers the price target from $92 to $91.

CRNX

Citizens Capital Markets Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $91

Banco Latinamericano shares are trading higher after the company announced a dividend increase.

Sunrun shares are trading lower after the company reported worse-than-expected Q4 revenue results.

CRBG

Corebridge Financial shares are trading higher after Morgan Stanley upgraded its rating on the stock from Equal-Weight to Overweight and its price target from $35 to $43.

LOKVU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

FERAU

Citizens Capital Markets analyst Jason Butler maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and raises the price target from $696 to $701.

ARGX

Citizens Capital Markets Maintains Outperform on argenx, Raises Price Target to $701

PNTG

Pennat Group shares are trading lower. The company reported Q4 financial results.

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Outperform and maintains $2.25 price target.

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

GFL Environmental shares are trading higher after TD Cowen raised its price target on the stock from $53 to $60.

Press Releases

Binah Capital Group Celebrates Successful Completion of Public Listing with Opening Bell Ringing Ceremony at Nasdaq

Binah Capital Group, Inc. Announces Receipt of Nasdaq Non-Compliance Notice

PKS Investments, a Subsidiary of Binah Capital Group, Recognized as One of Albany's Best Places to Work

Management

Binah Capital Group Chief Executive Officer Recognized by the Prestigious InvestmentNews Hot List

Binah Capital Recognized Among Industry Leaders in the Financial Planning's Top Deal Makers List "Top IBD Moves and M&A Deals of 2024"

Comments

Binah Capital Group

Intérêt court

Binah Capital Group (NASDAQ:BCG) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL